CB-010
- Generic Name
- CB-010
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
CB-010 is a CRISPR-edited allogeneic CAR-T cell therapy targeting CD19. It is being investigated for the treatment of follicular lymphoma.
- Associated Conditions
- -
- Associated Therapies
- -
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients with Refractory Systemic Lupus Erythematosus (GALLOP)
Phase 1
Not yet recruiting
- Conditions
- Systemic Lupus ErythematosusLupusLupus ErythematosusLupus Nephritis
- Interventions
- First Posted Date
- 2024-12-31
- Last Posted Date
- 2024-12-31
- Lead Sponsor
- Caribou Biosciences, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT06752876
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath